Featured
-
-
Outlook |
Perspective: Learning to share
Genomics can provide powerful tools against cancer — but only once clinical information can be made broadly available, says John Quackenbush.
- John Quackenbush
-
News Q&A |
The view from the bottom of the patent cliff
Menelas Pangalos, AstraZeneca’s head of discovery research, talks about life after patent expiration — and what it will take the turn the company around.
- Heidi Ledford
-
News |
Trade deal to curb generic-drug use
Tighter patent rules could raise drug costs in poor countries.
- Amy Maxmen
-
News |
Generic HIV drugs will widen US treatment net
Upcoming patent expiries stand to make medicines cheaper — although less convenient.
- Amy Maxmen
-
News |
US drug agency spied on scientists
Food and Drug Administration monitored five employees, defying promises about whistle-blower protection.
- Meredith Wadman
-
News Explainer |
The great gene-patent debate
How the Myriad Genetics gene-patent case might affect personalized medicine.
- Amy Maxmen
-
News |
UK funders seek integrity upgrade
Grants will be awarded in line with national framework on research conduct.
- Daniel Cressey
-
Spotlight |
Spotlight on Immunology / Vaccines
-
Career Brief |
UK drug development
Venture-capital funding in the United Kingdom represents a boost for translational research.
-
Career Brief |
Postdoc opportunities
Pfizer collaboration will provide opportunities to work with industry.
-
News |
Funding uncertainty strands Spain's young scientists
Delayed decisions disrupt international collaborations.
- Lucas Laursen
-
Seven Days |
Seven days: 27 January–2 February 2012
The week in science: sequencing stock rebounds after takeover bid for Illumina; drug companies and nations team up against neglected diseases; and turmoil at the Global Fund.
-
-
News |
Cutbacks threaten HIV gains
Wealthy nations have reduced contributions to global research and treatment programmes.
- Meredith Wadman
-
News |
Scientists, meet capitalists
US agencies and scientific societies aim to create jobs by teaching researchers how to be entrepreneurs.
- Eugenie Samuel Reich
-
News |
Blockbuster drug bows out
Pharmaceutical industry anxiously struggles to retool as Lipitor patent expires.
- Heidi Ledford
-
News |
Drug research feels Europe's pain
Pharma companies see drops in revenue amid European austerity measures.
- Daniel Cressey
-
News |
Seven days: 28 October–3 November
The week in science: United States cancels UNESCO funding; proton-smashing ends for the year at the Large Hadron Collider; and Britain's Royal Society opens up its journal archive.
-
News |
Research cuts hit the DNA business
Makers of sequencing machines hope for profits in the clinic.
- Erika Check Hayden
-
News |
Indian generics giants set sights on Japan
Country's drug industry looks to exploit growing Japanese market while fending off tougher European patents.
- Priya Shetty
-
-
Spotlight |
Spotlight on Luxembourg
-
News |
Genzyme deal set to alter biotech landscape
Maintaining innovative culture will be a key challenge for new owners of industry stalwart.
- Heidi Ledford
-
News |
Licence rules hinder work on rare disease
Animal model off-limits to Rett-syndrome researchers.
- Erika Check Hayden
-
News |
A new method of drug discovery
Public–private partnership proposed to develop pharmaceuticals.
- Daniel Cressey
-
News |
Lack of support keeps African discoveries languishing in labs
Institutional frameworks must be improved to save stagnant technologies
- Linda Nordling
-
Editorial |
Treated fairly?
Moves to price new pharmaceuticals sensibly shouldn't damage the industry's health.
-
News |
Drug giants turn their backs on RNA interference
A once much-touted technique faces a difficult transition to the clinic.
- Heidi Ledford
-
News |
Drugs to treat HIV found to prevent infection
Antiretroviral drugs shown to cut HIV transmission to men at high risk.
- Alla Katsnelson
-
News |
Funding woes afflict African herbal therapy institute
Promising therapies in limbo after donor money runs out.
- Deborah-Fay Ndhlovu
-
News |
'Biosimilar' drugs poised to penetrate market
Draft regulations will pave the way for copycat antibodies and other large molecules.
- Heidi Ledford
-
News |
UK drug-price overhaul set to shake up pharmaceutical industry
A bad value-based pricing system could threaten innovation.
- Daniel Cressey
-
Correspondence |
Clarifying knowledge ownership in Europe's medicines initiative
- Kim De Rijck
- & Michel Goldman
-
News |
Protein mapping gains a human focus
Next phase of the US Protein Structure Initiative enlists biologists to help crack tough human receptors.
- Heidi Ledford
-
News |
Universities shun Europe's drug initiative
Intellectual-property rules push researchers away.
- Natasha Gilbert
-
Editorial |
Change of purpose
The United States should protect investments used to find new uses for old drugs.
-
News |
Neglected diseases fund touted
Initiative seeks billions of dollars to develop promising drugs and vaccines.
- Declan Butler
-
News |
NIH may allow stem-cell lines from younger embryos
Lines derived from pre-blastocyst stage embryos could be eligible for agency funding.
- Meredith Wadman
-
Column |
Drug discovery for the masses
To sustain innovation, pharmaceutical companies will have to change the way they do research, says Derek Lowe. But does anyone know what changes to make?
- Derek Lowe
-
News |
China's patents push
Asia defies patent-filing downturn as global economy slips.
- David Cyranoski
-
News |
Britain grants patent for iPS cells
The first issued outside Japan for reprogrammable stem cells credits different inventors.
- Sabin Russell
-
News |
NIH scrutinizes drug-company payments at Baylor
Funding agency raises 'serious concerns' about conflicts of interest.
- Brendan Borrell
Epidemiology: The complexities of epilepsy